Informed Consent
Item
must give signed written informed consent
boolean
C0021430 (UMLS CUI [1])
Age
Item
must be of age 18 years or older
boolean
C0001779 (UMLS CUI [1])
Adenocarcinoma of prostate
Item
histologically confirmed adenocarcinoma of the prostate
boolean
C0007112 (UMLS CUI [1])
Luteinizing Hormone-releasing Hormone Agonist | Testosterone measurement | Orchiectomy
Item
must be currently receiving lhrh agonists and have castrate levels of testosterone or have had an orchiectomy
boolean
C1518041 (UMLS CUI [1])
C0523912 (UMLS CUI [2])
C0029189 (UMLS CUI [3])
Raised prostate specific antigen | Androgen Antagonists Withdrawal
Item
must have had rise in psa despite anti-androgen withdrawal
boolean
C0178415 (UMLS CUI [1])
C0002842 (UMLS CUI [2,1])
C2349954 (UMLS CUI [2,2])
Raised prostate specific antigen Quantity Post Hormone Therapy
Item
must exhibit two consecutive rises in psa after the last hormonal manipulation
boolean
C0178415 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C0687676 (UMLS CUI [1,3])
C0279025 (UMLS CUI [1,4])
Prostate-Specific Antigen Minimum
Item
minimum psa > 5mg/dl
boolean
C0138741 (UMLS CUI [1,1])
C1524031 (UMLS CUI [1,2])
Karnofsky Performance Status
Item
kps > 80%
boolean
C0206065 (UMLS CUI [1])
Chemotherapy Quantity
Item
up to one prior chemotherapy treatments allowed
boolean
C0392920 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
Life Expectancy
Item
life expectancy of greater than 6 months
boolean
C0023671 (UMLS CUI [1])
Hormone Therapy | LHRH
Item
concomitant hormonal therapy other than an lhrh
boolean
C0279025 (UMLS CUI [1])
C0023610 (UMLS CUI [2])
Non-compliance
Item
noncompliance
boolean
C0457432 (UMLS CUI [1])
Platelet Count measurement
Item
platelets less than 100 x 10e9 /l
boolean
C0032181 (UMLS CUI [1])
International Normalized Ratio
Item
international normalization ratio (inr) greater than 1.6
boolean
C0525032 (UMLS CUI [1])
Elevated total bilirubin
Item
total bilirubin greater than 1.5 x ulrr
boolean
C0741494 (UMLS CUI [1])
Alanine aminotransferase increased | Aspartate aminotransferase increased | Secondary malignant neoplasm of liver
Item
alt or ast greater than 2.5 x ulrr if no demonstrable liver metastases or greater than 5.0 x ulrr in presence of liver metastases
boolean
C0151905 (UMLS CUI [1])
C0151904 (UMLS CUI [2])
C0494165 (UMLS CUI [3])
Bleeding tendency | Disseminated Intravascular Coagulation | Clotting factor deficiency
Item
history of bleeding diathesis (ie, disseminated intravascular coagulation [dic], clotting factor deficiency)
boolean
C1458140 (UMLS CUI [1])
C0012739 (UMLS CUI [2])
C0272315 (UMLS CUI [3])
Anticoagulant therapy Long-term | Antiplatelet therapy
Item
history of long-term anticoagulant therapy (other than antiplatelet therapy)
boolean
C0150457 (UMLS CUI [1,1])
C0443252 (UMLS CUI [1,2])
C1096021 (UMLS CUI [2])
Hypersensitivity Fulvestrant Excipient | Hypersensitivity Fulvestrant inactive ingredient | Castor oil allergy | Mannitol allergy
Item
history of hypersensitivity to active or inactive excipients of fulvestrant (ie, castor oil or mannitol)
boolean
C0020517 (UMLS CUI [1,1])
C0935916 (UMLS CUI [1,2])
C0015237 (UMLS CUI [1,3])
C0020517 (UMLS CUI [2,1])
C0935916 (UMLS CUI [2,2])
C1552019 (UMLS CUI [2,3])
C0571232 (UMLS CUI [3])
C0571922 (UMLS CUI [4])